Colorectal cancer cells carrying the BRAFV600E mutation can overcome MEK inhibition by amplification of BRAFV600E, increasing levels of BRAFV600E protein to activate more MEK and sustain ERK1/2 activity (11,12). This evidence concerns the gene MAPK3 and colorectal cancer.